

Pedro Coelho Barata

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6649636/pedro-coelho-barata-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

150
papers

1,335
citations

16
h-index

34
g-index

167
ext. papers

1,897
ext. citations

4.5
avg, IF

5.22
L-index

#	Paper	IF	Citations
150	Treatment of renal cell carcinoma: Current status and future directions. <i>Ca-A Cancer Journal for Clinicians</i> , 2017 , 67, 507-524	220.7	321
149	RNA-targeted therapeutics in cancer clinical trials: Current status and future directions. <i>Cancer Treatment Reviews</i> , 2016 , 50, 35-47	14.4	110
148	Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma 2018 , 6, 9		105
147	Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. <i>Cancer</i> , 2018 , 124, 2115-2124	6.4	51
146	Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance. <i>Annals of Oncology</i> , 2017 , 28, 2458-2463	10.3	49
145	Physical and chemical stimuli-responsive drug delivery systems: targeted delivery and main routes of administration. <i>Current Pharmaceutical Design</i> , 2013 , 19, 7169-84	3.3	41
144	Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. <i>Cancer</i> , 2020 , 126, 1208-1216	6.4	37
143	Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab 2018 , 6, 107		36
142	PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy. <i>Cancers</i> , 2020 , 12,	6.6	35
141	Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 118-128	9.7	33
140	Metastatic castration-sensitive prostate cancer: Abiraterone, docetaxel, or α - <i>Cancer</i> , 2019 , 125, 1777-1788	8.4	28
139	A case of post-radiotherapy gastritis: radiation does not explain everything. <i>Case Reports in Oncology</i> , 2015 , 8, 9-14	1	28
138	Outcomes and satisfaction of two optional cadaveric dissection courses: A 3-year prospective study. <i>Anatomical Sciences Education</i> , 2017 , 10, 127-136	6.8	27
137	Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA 2020 , 8,		25
136	The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2018 , 119, 160-163	8.7	25
135	Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study. <i>European Urology Oncology</i> , 2020 , 3, 695-699	6.7	19
134	Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e879-e892	3.3	16

133	A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC). <i>Investigational New Drugs</i> , 2018 , 36, 451-457	4.3	15
132	Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. <i>Oncotarget</i> , 2018 , 9, 33232-33243	3.3	15
131	Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 413-419.e1	3.3	13
130	Improving attribution of adverse events in oncology clinical trials. <i>Cancer Treatment Reviews</i> , 2019 , 76, 33-40	14.4	12
129	Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 1623-1630	12.9	12
128	Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma. <i>Targeted Oncology</i> , 2018 , 13, 599-609	5	12
127	Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer. <i>Investigational New Drugs</i> , 2019 , 37, 1231-1238	4.3	11
126	Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer. <i>Oncologist</i> , 2020 , 25, 327-333	5.7	11
125	Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies. <i>Targeted Oncology</i> , 2018 , 13, 353-361	5	11
124	Seizure frequency in more than 180,000 treatment sessions with hyperbaric oxygen therapy - a single centre 20-year analysis. <i>Diving and Hyperbaric Medicine</i> , 2019 , 49, 167-174	1	11
123	Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. <i>Journal of Urology</i> , 2020 , 204, 63-70	2.5	11
122	Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer. <i>Investigational New Drugs</i> , 2019 , 37, 331-337	4.3	11
121	Symptom clusters and survival in Portuguese patients with advanced cancer. <i>Cancer Medicine</i> , 2016 , 5, 2731-2739	4.8	10
120	Nivolumab treatment for patients with non-clear cell renal cell carcinoma: A multicenter retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4586-4586	2.2	10
119	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021 , 4, 464-472	6.7	9
118	Targeted Next-Generation Sequencing in Men with Metastatic Prostate Cancer: a Pilot Study. <i>Targeted Oncology</i> , 2018 , 13, 495-500	5	9
117	Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer. <i>Investigational New Drugs</i> , 2019 , 37, 559-566	4.3	8
116	Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. <i>Prostate</i> , 2021 , 81, 433-439	4.2	8

115	Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy. <i>Prostate</i> , 2018 , 78, 1035-1041	4.2	7
114	Clinical outcome of patients (Pts) with metastatic renal cell carcinoma (mRCC) progressing on front-line immune-oncology based combination (IO-COMBO) regimens.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 613-613	2.2	6
113	Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2020 , 12,	6.6	6
112	Evaluation of Response to Enzalutamide Consecutively After Abiraterone Acetate/Prednisone Failure in Patients With Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 429-436	3.3	6
111	Breast cancer presents with a paraneoplastic neurologic syndrome. <i>Case Reports in Oncology</i> , 2012 , 5, 616-21	1	5
110	Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort. <i>Frontiers in Oncology</i> , 2020 , 10, 581189	5.3	5
109	Repurposing ketoconazole as an exosome directed adjunct to sunitinib in treating renal cell carcinoma. <i>Scientific Reports</i> , 2021 , 11, 10200	4.9	5
108	Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide. <i>Cancer Management and Research</i> , 2019 , 11, 7253-7262	3.6	4
107	Continuous infusion 5-fluorouracil (5FU) as a novel treatment for heavily pretreated prostate cancer patients: An update.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 319-319	2.2	4
106	Evaluation of the genomic alterations in the androgen receptor gene during treatment with high-dose testosterone for metastatic castrate-resistant prostate cancer. <i>Oncotarget</i> , 2020 , 11, 15-21	3.3	4
105	Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?. <i>Cancers</i> , 2021 , 13,	6.6	4
104	TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, 148-154	3.3	4
103	Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study. <i>Investigational New Drugs</i> , 2018 , 36, 1085-1092	4.3	4
102	Pazopanib-Induced Cutaneous Leukocytoclastic Vasculitis: An Exclusion Diagnosis of a Multidisciplinary Approach. <i>Case Reports in Oncology</i> , 2017 , 10, 1041-1049	1	4
101	Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 425-433	3.3	4
100	Relationship between serum markers and volume of liver metastases in castration-resistant prostate cancer. <i>Cancer Treatment and Research Communications</i> , 2019 , 20, 100151	2	3
99	Intra-patient heterogeneity in urothelial cancer (UC) circulating tumor cells (CTC) and PDL1 expression to identify biomarkers of response and new therapeutic targets: A pilot study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4537-4537	2.2	3
98	Clinicopathologic factors, treatment patterns, and outcomes in micropapillary urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 439-439	2.2	3

97	The Evolving Treatment Landscape of Advanced Renal Cell Carcinoma in Patients Progressing after VEGF Inhibition. <i>Journal of Kidney Cancer and VHL</i> , 2017 , 4, 10-18	1.4	3
96	Update on First-Line Combination Treatment Approaches in Metastatic Clear-Cell Renal Cell Carcinoma. <i>Current Treatment Options in Oncology</i> , 2021 , 22, 15	5.4	3
95	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. <i>BJU International</i> , 2021 , 128, 196-205	5.6	3
94	Differential activity of PARP inhibitors in BRCA1- versus BRCA2-altered metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 100-100	2.2	3
93	PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 ,	6.2	3
92	Precision therapy in advanced urothelial cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019 , 4, 81-93	1.6	2
91	Long-Term Disease Control Using Taxane/Platinum-Based Chemotherapy in CDK12-Mutated Advanced Prostate Cancer. <i>Oncologist</i> , 2020 , 25, e1421-e1422	5.7	2
90	Circulating tumor (ct)-DNA alterations in urothelial/bladder cancer (UC/BC): Updates on a dynamic genomic landscape.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4534-4534	2.2	2
89	Circulating tumor (ct)-DNA alterations in advanced urothelial carcinoma: Association with outcomes and evolution with therapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 334-334	2.2	2
88	First-line PD-1/PD-L1 inhibitor monotherapy for advanced renal cell carcinoma (aRCC): A multi-institutional cohort.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e17109-e17109	2.2	2
87	Identifying Prostate Surface Antigen Patterns of Change in Patients with Metastatic Hormone Sensitive Prostate Cancer Treated with Abiraterone and Prednisone. <i>Targeted Oncology</i> , 2020 , 15, 477-483	5.3	2
86	Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients. <i>Prostate</i> , 2021 , 81, 427-432	4.2	2
85	Differential Activity of PARP Inhibitors in - Versus -Altered Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	2
84	Change in neutrophil to lymphocyte ratio (NLR) as a predictor of treatment failure in renal cell carcinoma patients: Analysis of the IROC (Investigating RCC Outcomes) cohort.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 344-344	2.2	2
83	Stimuli-responsive nanosystems for drug-targeted delivery 2018 , 155-209		2
82	Combination of Tipifarnib and Sunitinib Overcomes Renal Cell Carcinoma Resistance to Tyrosine Kinase Inhibitors via Tumor-Derived Exosome and T Cell Modulation.. <i>Cancers</i> , 2022 , 14,	6.6	2
81	A systematic review of immune checkpoint inhibitors (ICI) in non-clear cell renal cell cancer (nccRCC) subtypes.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 353-353	2.2	2
80	High-Dose Testosterone and Radium-223 Response in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 476-479	3.3	1

79	Association of mTOR Pathway Markers and Clinical Outcomes in Patients with Intermediate-/High-risk Prostate Cancer: Long-Term Analysis. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 366-372	3.3	1
78	Skeletal-Related Events in Patients with Metastatic Renal Cell Carcinoma: A Systematic Review. <i>Kidney Cancer</i> , 2020 , 4, 93-102	0.6	1
77	Non-metastatic castration-resistant prostate cancer: current status and future directions. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 513-522	3.5	1
76	Next Generation of Androgen Deprivation Therapy Combined With Radiotherapy for N0 M0 Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020 , 26, 21-28	2.2	1
75	Corticosteroid sensitivity in gliomatosis cerebri delays diagnosis. <i>Practical Neurology</i> , 2015 , 15, 309-11	2.4	1
74	Pembrolizumab (pembro) in heavily pretreated metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 255-255	2.2	1
73	First-line PD1/PD-L1 inhibitors for platinum-ineligible advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 432-432	2.2	1
72	Outcomes of patients (pts) with metastatic urothelial cancer (mUC) and poor performance status (PS) receiving anti-PD(L)1 agents.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4525-4525	2.2	1
71	Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer. <i>Cancer Treatment and Research Communications</i> , 2020 , 24, 100193	2	1
70	PD-L1 Expression and Treatment Implications in Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review. <i>Kidney Cancer</i> , 2021 , 5, 31-46	0.6	1
69	Differences in the tumor genomic landscape between African Americans (AA) and Caucasians (CA) advanced prostate cancer (aPC) patients (pts) by comprehensive genomic profiling (CGP) of cell-free DNA (cfDNA).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 5058-5058	2.2	1
68	Efficacy outcomes of nivolumab + cabozantinib versus pembrolizumab + axitinib in patients with advanced renal cell carcinoma (aRCC): Matching-adjusted indirect comparison (MAIC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4578-4578	2.2	1
67	Blood-based tumor mutational burden from circulating tumor DNA (ctDNA) across advanced solid malignancies using a commercially available liquid biopsy assay.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3040-3040	2.2	1
66	Artificial Intelligence in Cancer Care: Legal and Regulatory Dimensions. <i>Oncologist</i> , 2021 , 26, 807-810	5.7	1
65	Efficacy of enfortumab vedotin in advanced urothelial cancer: Retrospective analysis of the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) Study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 443-443	2.2	1
64	Angiogenic and T-effector subgroups identified by gene expression profiling (GEP) and propensity for PBRM1 and BAP1 alterations in clear cell renal cell carcinoma (ccRCC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 343-343	2.2	1
63	Evaluation of cabozantinib (cabo) in combination with direct oral anticoagulants (DOAC) or low molecular weight heparin (LMWH) in renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 291-291	2.2	1
62	The Costly War Against Cancer Treatment: The Example of Metastatic Renal Cell Carcinoma in Portugal. <i>Acta Medica Portuguesa</i> , 2018 , 31, 373-375	1.4	1

61	Molecular alterations across sites of metastasis in patients with renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 287-287	2.2	1
60	Pathologic outcomes at cytoreductive nephrectomy (CN) following immunotherapy (IO) for patients with advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 334-334	2.2	1
59	Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin.. <i>Clinical Genitourinary Cancer</i> , 2021 ,	3.3	1
58	Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. <i>Cancer</i> , 2021 ,	6.4	1
57	A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer. <i>Kidney Cancer</i> , 2022 , 1-13	0.6	1
56	A Case Report with Severe Thrombocytopenia Induced by Axitinib. <i>Case Reports in Hematology</i> , 2020 , 2020, 7520783	0.7	0
55	Systematic Review of Treatment of Metastatic Non-Clear Cell Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2022 , 1-16	0.6	0
54	Real-world experience with atezolizumab (atezo) in advanced urothelial cancer (UC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, e16031-e16031	2.2	0
53	Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer.. <i>Oncologist</i> , 2022 , 27, 220-227	5.7	0
52	Outcomes and patterns of disease progression in metastatic renal cell carcinoma patients treated with nivolumab.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 654-654	2.2	0
51	Association of circulating tumor (ct)-DNA genomic alterations (GA) with outcomes in metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 4540-4540	2.2	0
50	Association of ATM mutations in metastatic prostate cancer with differential genomic alteration profiles from homologous recombination deficient and proficient tumors.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 5063-5063	2.2	0
49	Implications of the United States Preventive Services Task Force Recommendations on Prostate Cancer Stage Migration. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, e12-e16	3.3	0
48	A dual drug therapy for sunitinib resistant RCC: An in vitro analysis.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 340-340	2.2	0
47	Comprehensive genomic profiling of penile squamous cell carcinoma and impact of HPV status on immune-checkpoint inhibition-related biomarkers.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 4-4	2.2	0
46	Blood-based tumor mutational burden from circulating tumor DNA and immune checkpoint inhibitors in advanced prostate cancer.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 165-165	2.2	0
45	SWOG S1931 (PROBE): Phase III randomized trial of immune checkpoint inhibitor (ICI) combination regimen with or without cytoreductive nephrectomy (CN) in advanced renal cancer.. <i>Journal of Clinical Oncology</i> , 2022 , 40, TPS402-TPS402	2.2	0
44	Repeat Treatment of Patients With Advanced Urothelial Carcinoma With Immune Checkpoint Inhibitors Following Prior Progression on a Checkpoint Inhibitor Regimen: A Case Series.. <i>Clinical Genitourinary Cancer</i> , 2021 ,	3.3	0

43	Tumores neuroendócrinos pancreáticos: análise retrospectiva de 12 anos de experiência do Instituto Português de Oncologia de Lisboa. <i>Revista Portuguesa De Endocrinologia Diabetes E Metabolismo</i> , 2013 , 8, 2-8	0
42	EPID-03. SINGLE INSTITUTIONAL CLINICAL AND GENETIC ANALYSIS OF METASTATIC PROSTATE CANCER WITH AND WITHOUT BRAIN METASTASES. <i>Neuro-Oncology</i> , 2020 , 22, ii78-ii79	1
41	Atezolizumab (atezo) and subsequent therapies in patients (Pts) with metastatic urothelial carcinoma (mUC) outside clinical trials.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 432-432	2.2
40	The association between HSD3B1 genotype and steroid metabolism in normal and prostate cancer (PCa) tissue.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS155-TPS155	2.2
39	Response to platinum-based therapy (PBT) and immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts) with genomic alterations (GA) in homologous recombination repair (HRR) genes.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 447-447	2.2
38	Treatment patterns for metastatic hormone-sensitive prostate cancer (mHSPC) progressing after up-front docetaxel in combination with androgen deprivation therapy (D-ADT).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 305-305	2.2
37	Immunological correlates of response to immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 454-454	2.2
36	Cisplatin-based neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) in patients (pts) with impaired renal function.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 446-446	2.2
35	The impact of switching systemic treatment after radiosurgery (SBRT) for oligo-progressive, metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 599-599	2.2
34	Serial changes in PD1/PDL1 expression in metastatic urothelial carcinoma (mUC) patients (pts) treated with immune checkpoint blockade (CPB).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 109-109	2.2
33	Predictors of progressive disease (PD) and subsequent outcomes in metastatic renal cell carcinoma (mRCC) patients (pts) treated with nivolumab (nivo).. <i>Journal of Clinical Oncology</i> , 2018 , 36, e16563-e16563	2.2
32	Genomic changes of AR in ctDNA prior to enzalutamide in men with mCRPC after abiraterone acetate.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 320-320	2.2
31	TP53 mutations in circulating tumor DNA in men with metastatic castration-resistant prostate cancer mCRPC.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 249-249	2.2
30	First-line PD(L)1 inhibitors for platinum-ineligible advanced urothelial carcinoma (aUC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, e16024-e16024	2.2
29	AR changes in circulating-tumor DNA (ctDNA) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with high-dose testosterone.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5058-5058	2.2
28	Development of Molecularly Targeted Agents in Early Phase Clinical Trials 2020 , 199-220	
27	Considerations for the Attribution and Management of Toxicities in Phase I Clinical Trials 2020 , 109-118	
26	Cisplatin-based neoadjuvant chemotherapy (NAC) in bladder cancer patients (Pts) with borderline renal function: Implications for clinical practice.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 390-390	2.2

- 25 Differential responses to taxanes and PARP inhibitors (PARPi) in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer (mCRPC) patients (pts).. *Journal of Clinical Oncology*, **2021**, 39, 5040-5040 2.2
- 24 Immune checkpoint inhibitors (ICI) in advanced sarcomatoid renal cell carcinoma (sRCC): A multicenter study.. *Journal of Clinical Oncology*, **2021**, 39, 4568-4568 2.2
- 23 Baseline pathogenic mutations in non-AR/non-TP53 genes and prediction of response to high-dose testosterone.. *Journal of Clinical Oncology*, **2021**, 39, 146-146 2.2
- 22 Real-world prevalence of homologous recombination repair gene (BRCA1/2 and ATM) mutations (HRRm) in patients (pts) with advanced prostate cancer (aPC) as detected by comprehensive genomic profiling (CGP) of circulating cell-free DNA (cfDNA).. *Journal of Clinical Oncology*, **2021**, 39, 256-256 2.2
- 21 Differences in the genomic landscape of advanced prostate cancer (aPC) patients (pts) with BRCA1 versus BRCA2 mutations as detected by machine learning analysis of the comprehensive genomic profile (CGP) of cell-free DNA (cfDNA).. *Journal of Clinical Oncology*, **2021**, 39, 162-162 2.2
- 20 PD-L1 inhibition with avelumab plus abiraterone acetate or enzalutamide in African Americans with metastatic castrate-resistant prostate cancer (mCRPC).. *Journal of Clinical Oncology*, **2021**, 39, 87-87 2.2
- 19 Multi-institutional evaluation of the clinical outcomes and genomic correlates of African Americans with metastatic castration-sensitive prostate cancer (mCSPC).. *Journal of Clinical Oncology*, **2021**, 39, 17-17 2.2
- 18 Landscape of circulating tumor DNA (ctDNA) abnormalities in advanced prostate cancer (aPCa): Distinctions in African American (AA) versus Caucasian (Ca) patients.. *Journal of Clinical Oncology*, **2021**, 39, 156-156 2.2
- 17 18F-fluciclovine positron emission tomography (PET) in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate.. *Journal of Clinical Oncology*, **2021**, 39, TPS171-TPS171² 2.2
- 16 ctDNA pathogenic variants (PVs) in homologous recombination repair (HRR) genes in patients with metastatic CRPC.. *Journal of Clinical Oncology*, **2021**, 39, 138-138 2.2
- 15 Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients.. *Journal of Clinical Oncology*, **2021**, 39, 143-143 2.2
- 14 Treatment response in the intact primary renal mass (P-Rmass) and its relationship to the overall response to treatment in patients with metastatic renal cell carcinoma (mRCC).. *Journal of Clinical Oncology*, **2021**, 39, 329-329 2.2
- 13 The Challenges of Implementing Multiarmed Early Phase Oncology Clinical Trials **2018**, 47-55
- 12 Comparative ctDNA analyses of African-American and Caucasian patients with CRPC.. *Journal of Clinical Oncology*, **2022**, 40, 24-24 2.2
- 11 Implications of androgen receptor (AR) alterations identified by genomic testing of tissue and blood from advanced prostate cancer (aPC) patients (pts).. *Journal of Clinical Oncology*, **2022**, 40, 138-138² 2.2
- 10 DNA damaging therapies in patients (pts) with prostate cancer (PC) and pathogenic alterations in homologous recombination repair (HRR) genes.. *Journal of Clinical Oncology*, **2022**, 40, 129-129 2.2
- 9 Circulating tumor DNA responses to high-dose testosterone injections in CRPC patients.. *Journal of Clinical Oncology*, **2022**, 40, 173-173 2.2
- 8 Molecular and immune landscape of FH-mutated kidney cancer.. *Journal of Clinical Oncology*, **2022**, 40, 382-382 2.2

- 7 Treatment trends among men with metastatic castration sensitive prostate cancer (mCSPC): Results from the US component of an international study.. *Journal of Clinical Oncology*, **2022**, 40, 66-66 2.2
- 6 Impact of neoadjuvant immune checkpoint inhibitor therapy on primary tumor size and complexity: Correlation with surgical quality and short term oncological outcomes.. *Journal of Clinical Oncology*, **2022**, 40, 390-390 2.2
- 5 PATRIOT II: An ambispective, observational, multicenter, 2-cohort study of avelumab (Ave) first-line maintenance (1LM) in locally advanced/metastatic urothelial carcinoma (la/mUC) in the United States.. *Journal of Clinical Oncology*, **2022**, 40, TPS578-TPS578 2.2
- 4 68ga-PSMA-11 patients with newly diagnosed and recurrent prostate cancer (Firefly).. *Journal of Clinical Oncology*, **2022**, 40, TPS189-TPS189 2.2
- 3 Longitudinal ctDNA alterations in germline positive CRPC patients.. *Journal of Clinical Oncology*, **2022**, 40, 275-275 2.2
- 2 Treatment (tx) patterns among men with metastatic castration resistant prostate cancer (mCRPC) in the United States (US).. *Journal of Clinical Oncology*, **2022**, 40, 52-52 2.2
- 1 Evaluation of ctDNA alterations in mCRPC patients with germline pathogenic mutations.. *Journal of Clinical Oncology*, **2022**, 40, 177-177 2.2